BRIEF—Dutch-German collaboration in manufacturing cancer vaccines

DCPrime, a clinical-stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma, a German contract manufacturing organization in gene and cell therapies, have entered into a strategic manufacturing agreement.

The collaboration involves clinical batch production and the development of a commercial scale manufacturing process of cancer vaccines based on the Dutch company's technology platform, DCOne.

Only recently, apceth successfully passed an inspection by the District Government of Upper Bavaria and the Paul-Ehrlich-Institute for the manufacturing license for production of DCP-001, DCPrime’s lead program, enabling it to enter into a Phase II proof of concept study in acute myeloid leukemia.